Scale-Up Allogeneic Cell Therapies To Large Patient Populations

A key benefit of allogeneic cell therapy is that it provides a substantial and economical cost structure, increasing the ability to treat larger patient populations. As allogeneic cell therapy continues its exponential growth, a scale-appropriate model in early development stages for clinical trials, whilst aiding a smooth transition to large-scale cell manufacturing when necessary, is required.

During this webinar, Inbar Friedrich Ben-Nun, Director CGT Research and Development, Marcos Langtry, Head of Commercial Development Allogeneic, and Krishna Panchalingam, Associate Director Development Services CGT, discuss how to achieve your therapeutic and commercial goals utilizing a tried-and-tested standardized approach, combined with the latest technology and reliable analytics.

Learn about:

• Challenges associated with allogeneic cell therapy manufacturing
• How to successfully move through the product lifecycle using the latest technology combined with a tried-and-tested standardized approach
• How a stirred tank bioreactor platform can enable the transition to large-scale cell manufacturing designed to treat larger patient populations